https://www.selleckchem.com/pr....oducts/gsk2982772.ht
In 2017, all people with severe haemophilia B (PWSH in Ireland switched from standard half-life (SHL) recombinant FIX (rFIX) to rFIX Fc fusion protein (rFIXFc) prophylaxis. To evaluate prophylaxis regimens, bleeding rates and factor usage for two years of rFIXFc prophylaxis in a real-world setting. Data collected retrospectively from electronic diaries and medical records of PWSHB for a two-year period on rFIXFc prophylaxis were compared with paired baseline data on SHL rFIX treatment. 28 PWSHB (≥18years) were enrolled, and at swit
Like
Comment
Share
